Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Overview of Important Developments on the Evening of August 19

Overview of Important Developments on the Evening of August 19

金色财经金色财经2024/08/19 13:22
Show original

12:00-21:00 Keywords: Tether, Morgan Stanley, IBIT, FBTC, CZ release

1. Alex Lab: Since June 5, all ALEX revenue has been used to compensate users affected by the hacking incident;

2. Nigeria plans to introduce a cryptocurrency taxation bill by September;

3. Morgan Stanley: Fed Chair Powell may indicate that even with rate cuts, the policy will remain tight;

4. Grayscale SUI Trust Fund's asset management scale exceeds $600,000;

5. In the second quarter, the number of institutions holding IBIT and FBTC increased by 34% and 25% respectively quarter-on-quarter;

6. CZ may be released on September 29, 2024; 7. Tether will launch USDT on the Aptos chain;

8. SlowMist Cosine: The source of 4,046 suspected stolen BTC seems to be related to Genesis Global Trading.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

On Monday, storage chip concept stocks generally rose, with SanDisk (SNDK.US) up by 6%.

智通财经2026/08/17 13:51
U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds

On August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 study of Enhertu (trastuzumab deruxtecan) as a monotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has achieved highly positive results.

智通财经2026/08/17 12:56
AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds